Processing

Please wait...

Settings

Settings

1. WO2000040616 - METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41

Publication Number WO/2000/040616
Publication Date 13.07.2000
International Application No. PCT/US2000/000456
International Filing Date 10.01.2000
Chapter 2 Demand Filed 07.08.2000
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 39/21 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
21Retroviridae, e.g. equine infectious anemia virus
A61K 47/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C07K 14/16 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
16HIV-1
C07K 16/10 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 47/62
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C07K 16/1063
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
1036Retroviridae, e.g. leukemia viruses
1045Lentiviridae, e.g. HIV, FIV, SIV
1063env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Applicants
  • PANACOS PHARMACEUTICALS, INC. [US/US]; 217 Perry Parkway Gaithesburg, MD 20877, US
  • WEISS, Carol, D. [US/US]; US
Inventors
  • WEISS, Carol, D.; US
  • WILD, Carl, T.; US
Agents
  • COVERT, John, M. ; Sterne, Kessler, Goldstein & Fox P.L.L.C. Suite 600 1100 New York Avenue, N.W. Washington, DC 20005-3934, US
Priority Data
09/480,33607.01.2000US
60/115,40408.01.1999US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41
(FR) TECHNIQUES D'ELICITATION D'ANTICORPS NEUTRALISANTS CIBLANT gp41 DU VIH-1
Abstract
(EN)
The present invention is directed to the induction and characterization of a humoral immune response targeting 'entry-relevant' gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated $i(in vivo) as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against 'entry relevant' gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.
(FR)
La présente invention concerne l'induction et la caractérisation d'une réponse immunitaire humorale ciblant des structures gp41 « relatives à l'entrée ». Dans son aspect le plus large, la présente invention concerne des techniques permettant de déclencher une réponse d'anticorps neutralisants à un large spectre de souches et d'isolats du VIH. La présente invention concerne des conformations ou structures moléculaires particulières qui apparaissent à la surface cellulaire du VIH lors de l'entrée du virus dans la cellule hôte. Une telle réponse humorale peut être générée $i(in vivo) en tant que mesure de prophylaxie chez un patient, et vise à réduire ou à inhiber les capacités du VIH d'infecter des cellules saines dans le corps du patient. Une telle réponse peut également être utilisée en vue de développer des anticorps contre les structures gp41 relatives à l'entrée. Ces anticorps peuvent être utilisés à des fins thérapeutiques ainsi qu'en vue d'éclairer les mécanismes de l'entrée du VIH dans la cellule.
Also published as
NZ513424
ZA200106535
Latest bibliographic data on file with the International Bureau